COMMUNIQUÉS West-GlobeNewswire

GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA)
28/03/2019
-- Pooled Interim Phase 3 FINCH Program Data up to 24 Weeks and Phase 2b DARWIN 3 Long-Term Data Add to Evidence Supporting Filgotinib Safety Profile -- Foster City, Calif. and Mechelen, Belgium; March 28, 2019, 22.03 [...]
GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA)
28/03/2019
-- Pooled Interim Phase 3 FINCH Program Data up to 24 Weeks and Phase 2b DARWIN 3 Long-Term Data Add to Evidence Supporting Filgotinib Safety Profile -- Foster City, Calif. and Mechelen, Belgium; March 28, 2019, 22.03 [...]
GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY ENDPOINT IN THE PHASE 3 FINCH 3 STUDY IN METHOTREXATE-NAÏVE RHEUMATOID ARTHRITIS PATIENTS
28/03/2019
-- Filgotinib 100 mg and 200 mg Plus Methotrexate (MTX) Demonstrated Significantly Higher ACR20/50/70 Responses Than Methotrexate Alone -- -- Filgotinib Safety Profile Consistent With Previously Reported Results -- [...]
GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND KEY SECONDARY ENDPOINTS IN THE PHASE 3 FINCH 1 RHEUMATOID ARTHRITIS STUDY
28/03/2019
-- Filgotinib 100 mg and 200 mg Doses Demonstrated Significantly Higher ACR20/50/70 Responses than Placebo in Patients with Prior Inadequate Methotrexate Response -- -- Significant Inhibition of Radiographic Progression [...]
Align Technology and Straumann Group Settle Global ClearCorrect Patent Disputes and Sign Non-Binding Letter of Intent for Straumann to Distribute iTero Scanners
28/03/2019
Straumann agrees to immediate payment of $35 million settlement to Align Align and Straumann to dismiss existing patent disputes in US and UK Neodent to withdraw Brazil invalidity action against Align Align and [...]
Seelos Therapeutics Provides Update on Pipeline Developments and Corporate Highlights
28/03/2019
- First patient with Sanfilippo Syndrome expected to be dosed with Trehalose in an open-label phase IIb trial in 2Q 2019 – - Plan to initiate phase I study with intranasal racemic ketamine in Suicidality-PTSD in the [...]
Genfit: GENFIT Announces the Exercise in Full of the Option Granted to the Underwriters of its Global Offering and Nasdaq Global Select Market Listing to Purchase up to 997,500 Additional ADSs
28/03/2019
FOR IMMEDIATE RELEASE GENFIT Announces the Exercise in Full of the Option Granted to the Underwriters of its Global Offering and Nasdaq Global Select Market Listing to Purchase up to 997,500 Additional ADSs Gross [...]
Genfit : GENFIT annonce l’exercice intégral de l’option de surallocation dans le cadre de son introduction en bourse aux États-Unis
28/03/2019
CE COMMUNIQUÉ N’EST PAS DESTINÉ A ÊTRE PUBLIÉ, DISTRIBUÉ OU DIFFUSÉ, DIRECTEMENT OU INDIRECTEMENT, AUX ÉTATS-UNIS D’AMÉRIQUE NI À DES RESSORTISSANTS AMÉRICAINS (« U.S. PERSONS »), POUR LEUR BÉNÉFICE OU POUR LEUR COMPTE [...]
Amarin Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for Vascepa® (icosapent ethyl) to Reduce the Risk of Major Adverse Cardiovascular Events Based on Landmark REDUCE-IT™ Cardiovascular Outcomes Study
28/03/2019
BEDMINSTER, N.J., and DUBLIN, Ireland, March 28, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that, as planned, it [...]
Molecular Templates, Inc. Reports Fourth Quarter 2018 Financial Results
28/03/2019
AUSTIN, Texas, March 28, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular” or “Molecular Templates”), a clinical-stage oncology company focused on the discovery and development of the company [...]
Microbix Announces Annual Meeting Voting Results
28/03/2019
TORONTO, March 28, 2019 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, “ Microbix ” or the “ Company ”), an innovator of biological products and technologies, announces the voting results from the Annual [...]
Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of Neurology
28/03/2019
SAN DIEGO and CAMBRIDGE, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Voyager Therapeutics, Inc. (NASDAQ: VYGR) today announced the publication of interim results from the [...]
Equillium to Present at H.C. Wainwright Global Life Sciences Conference
28/03/2019
LA JOLLA, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that Dan Bradbury, Equillium’s [...]
Kezar Life Sciences Announces Presentations at Upcoming Scientific Conferences
28/03/2019
SOUTH SAN FRANCISCO, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat [...]
Forty Seven Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights
28/03/2019
-- Updated Data from Phase 1b/2 Trial of 5F9 in Combination with Rituximab in Relapsed/Refractory Non-Hodgkin’s Lymphoma (r/r NHL) Expected in Second Quarter of 2019 – -- Updated Data from Phase 1b Trial of 5F9 as a [...]
Dynavax Announces European Medicines Agency Accepts Marketing Authorization Application for HEPLISAV-B® for Prevention of Hepatitis B in Adults
28/03/2019
BERKELEY, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology [...]
SpineEX Begins Commercial Launch of its Sagittae Lateral Lumbar Interbody Fusion (LLIF) Device
28/03/2019
FREMONT, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- SpineEX Inc, a medical device company focused on the design, development and marketing of products for spine disorders, has officially begun the commercial launch of [...]
Achaogen Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
28/03/2019
-- ZEMDRI’s once-daily 30-minute infusion facilitating usage in the outpatient setting -- -- Company’s recent restructuring aimed at conserving capital to continue assessment of strategic alternatives -- -- Conference [...]
Capricor Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
28/03/2019
Plan to Report Interim Data from HOPE-2 Clinical Trial in Early Q3 To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, March 28, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a [...]

Pages